Related Experiment Video
Updated: Jan 25, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
11.5K
T2 Biologics for Chronic Obstructive Pulmonary Disease
Ahmed Yousuf1, Wadah Ibrahim1, Neil J Greening1
1Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Department of Infection, Immunity & Inflammation, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
Summary
Novel targeted therapies for chronic obstructive pulmonary disease (COPD) show promise. Type 2 (T2) biologics, like anti-IL-5(R), may benefit a subgroup of COPD patients with high eosinophil counts, but further research is needed.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a growing global health concern, projected to be the third leading cause of death and disability by 2030.
- Advances in understanding COPD pathophysiology have spurred the development of novel targeted therapies, including biologics and small molecules.
- Biologics targeting type 2 (T2)-mediated immunity have transformed severe asthma treatment, but no such therapies are currently approved for COPD.
Purpose of the Study:
- To investigate the potential efficacy of T2-directed biologics in treating COPD.
- To explore the role of T2 immunity and eosinophils in a subgroup of COPD patients.
- To assess the impact of anti-IL-5(R) biologics on COPD exacerbation frequency.
Main Methods:
- Review of current research on targeted therapies for COPD.
- Analysis of studies investigating T2 biologics, specifically anti-IL-5(R), in COPD patients.
- Correlation of treatment benefits with baseline blood eosinophil counts.
Main Results:
- T2 biologics, such as anti-IL-5(R), have shown modest reductions in exacerbation frequency in certain COPD patient subgroups.
- The potential benefit of these therapies appears related to the baseline blood eosinophil count.
- Observed benefits in COPD were smaller compared to those seen in severe asthma.
Conclusions:
- A subgroup of COPD patients, particularly those with elevated eosinophils, may potentially benefit from T2-directed biologics.
- The efficacy of anti-IL-5(R) and other T2 biologics in COPD requires further comprehensive investigation.
- Targeted immunotherapies represent a developing frontier in COPD management, necessitating continued research and clinical trials.
Related Concept Videos
01:22Chronic Obstructive Pulmonary Disease
2.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.4K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.6K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.6K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.3K
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
5.1K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
5.1K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.6K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.6K